



Integra LifeSciences Selected for Healogics iSupplySM Program

September 10, 2018

PLAINSBORO, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holdings Corporation](#) (Nasdaq:IART), a leading global medical technology company, today announced it has been selected as a primary provider for cellular-based tissue products within [Healogics](#)[®] Inc. new iSupply program. This program is exclusively available to Healogics' hospital partners and is focused on ensuring hospitals and patients receive the best value from wound care products commonly used in [Wound Care Centers](#)[®] and other sites of care.

Under Healogics new iSupply program, Integra will be a lead provider for cellular-based tissue products - [AmnioExcel](#)[®] [Amniotic Allograft Membrane](#), [AMNIOMATRIX](#)[®] [Amniotic Allograft Suspension](#), [PriMatrix](#)[®] [Dermal Repair Scaffold](#), [PriMatrix](#)[®] [Ag Antimicrobial Dermal Repair Scaffold](#) for the treatment of acute and chronic complex wounds, and [Omnigrift](#)[®] [Dermal Regeneration Matrix](#) for the treatment of diabetic foot ulcers. Cellular-based tissue products or skin substitutes are a group of FDA-regulated products that are designed to repair, restore or replace dermal and epidermal tissue architecture through different mechanisms of action. Integra's comprehensive suite of evidence-based product solutions are designed to support the body's natural restorative healing process. In addition, Integra's market leading total contact casting system, [TCC-EZ](#)[®] for offloading and protection of wounds, will also be available under the iSupply program.

"We are excited to be a primary provider of cellular-based tissue products for the iSupply program," said Robert T. Davis, Jr., corporate vice president and president, Orthopedics and Tissue Technologies. "Integra's products were selected through a rigorous analysis of published data and reviewed by Healogics' value analysis committee of leading wound care clinicians. This partnership with Healogics reinforces Integra's commitment to broader access to our advanced wound care products and improving outcomes for patients with chronic wounds."

"I have used Integra's line of advanced wound care products and believe they are a vital part of our iSupply Program," said Dr. Scott Covington, executive vice president of Provider Education at Healogics. "Through this program, we are able to offer high quality, cost-effective products to clinicians, who can confidently use these products to care for their patients."

About Integra

Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include [AmnioExcel](#)[®], [Bactiseal](#)[®], [Cadence](#)[®], [Certas](#)[™], [Codma](#)[®], [CUSA](#)[®], [DuraGen](#)[®], [DuraSeal](#)[®], [ICP Express](#)[®], [Integra](#)[®], [MediHoney](#)[®], [MicroFrance](#)[®], [PriMatrix](#)[®], [Salto Talaris](#)[®], [SurgiMend](#)[®], [TCC-EZ](#)[®], [Titan](#)[™] and [VersaTru](#)[™]. For the latest news and information about Integra and its brands, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2017 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

About Healogics

Headquartered in Jacksonville, Fla., Healogics is the nation's wound healing expert. Last year over 330,000 patients received advanced wound care through a nationwide network of 700 Wound Care Centers[®]. The Healogics team is made up of nearly 3,000 employees, 4,000 affiliated physicians and a [Healogics Specialty Physician](#) practice group of almost 300. In addition to the company's network of outpatient Centers, Healogics partners with over 300 skilled nursing facilities to care for patients with chronic wounds, and provides inpatient consults at 85 partner hospitals. As the industry leader, Healogics has the largest repository of chronic wound-specific patient data in the country. The [Healogics Wound Science Initiative](#), an effort launched in 2017 to provide peer-reviewed research, recognizes the value and relevance of big data and advanced analytics to drive continuous, collaborative learning towards a better understanding of how to efficiently utilize healthcare resources for patients with wounds. For additional information, please visit Healogics.com.

CONTACT: Integra LifeSciences Holdings Corporation

Investors

Pravara Emani
(609) 936-2488
pravara.emani@integralife.com

Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com

Media

Laurene Isip

609-750-7984

laurene.isip@integralife.com

Healogics Media Contact

Leslie Niblock

904-524-2695

leslie.niblock@healogics.com